Julia Lewis

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Hypertension management: special considerations in chronic kidney disease patients
    James P Smith
    Division of Nephrology, Vanderbilt University Medical Center, S 3223 MCN, Nashville, TN 37232 2372, USA
    Curr Hypertens Rep 6:462-8. 2004
  2. ncbi request reprint A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension
    Julia Lewis
    Nephrology Clinical Trials Center, Vanderbilt University Medical Center, 1211 21st Avenue South, 215 Medical Arts Building, Nashville, TN 37232 1371, USA
    J Am Soc Nephrol 15:3175-83. 2004
  3. doi request reprint Blood pressure control in chronic kidney disease: is less really more?
    Julia B Lewis
    Division of Nephrology and Hypertension, Department of Medicine, S 2332 Medical Center North, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2372, USA
    J Am Soc Nephrol 21:1086-92. 2010
  4. ncbi request reprint Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    Jackson T Wright
    Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
    JAMA 288:2421-31. 2002
  5. ncbi request reprint Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study
    Mohammed Sika
    Medicine, Vanderbilt, Nashville, TN, USA
    Am J Kidney Dis 50:78-89, 89.e1. 2007
  6. pmc Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis
    Tahira P Alves
    Department of Medicine, Division of Nephrology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Am Soc Nephrol 21:1361-9. 2010
  7. ncbi request reprint Microalbuminuria as a target to improve cardiovascular and renal outcomes
    Seema Basi
    Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 2372, USA
    Am J Kidney Dis 47:927-46. 2006
  8. pmc CRP polymorphisms and progression of chronic kidney disease in African Americans
    Adriana M Hung
    Vanderbilt University Medical Center, 1161 21st Avenue South and Garland, Division of Nephrology, S 3223 MCN, Nashville, TN 37232 2372, USA
    Clin J Am Soc Nephrol 5:24-33. 2010
  9. pmc A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report
    Allison B McCoy
    Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA
    Am J Kidney Dis 56:832-41. 2010
  10. doi request reprint Evaluation of renal artery stenosis in dialysis patients
    Jamie P Dwyer
    Division of Nephrology Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Semin Dial 22:519-23. 2009

Research Grants

  1. Treatment of Diabetic Nephropathy
    Julia Lewis; Fiscal Year: 2003
  2. Treatment of Diabetic Nephropathy
    Julia Lewis; Fiscal Year: 2004
  3. AASK Cohort Study
    Julia Lewis; Fiscal Year: 2007

Detail Information

Publications25

  1. ncbi request reprint Hypertension management: special considerations in chronic kidney disease patients
    James P Smith
    Division of Nephrology, Vanderbilt University Medical Center, S 3223 MCN, Nashville, TN 37232 2372, USA
    Curr Hypertens Rep 6:462-8. 2004
    ..Hopefully, with increased recognition of the unique aspects of treating hypertension in this population, end-stage renal disease and cardiovascular morbidity and mortality will be delayed or avoided in the millions of patients with CKD...
  2. ncbi request reprint A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension
    Julia Lewis
    Nephrology Clinical Trials Center, Vanderbilt University Medical Center, 1211 21st Avenue South, 215 Medical Arts Building, Nashville, TN 37232 1371, USA
    J Am Soc Nephrol 15:3175-83. 2004
    ..This has important implications for the design of clinical trials with renal outcomes...
  3. doi request reprint Blood pressure control in chronic kidney disease: is less really more?
    Julia B Lewis
    Division of Nephrology and Hypertension, Department of Medicine, S 2332 Medical Center North, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2372, USA
    J Am Soc Nephrol 21:1086-92. 2010
    ..A variety of observations suggest potential adverse events associate with achieving too low a BP in patients with chronic kidney disease, and ongoing randomized trials will have to establish the benefits or risks of meeting this goal...
  4. ncbi request reprint Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    Jackson T Wright
    Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
    JAMA 288:2421-31. 2002
    ..Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD...
  5. ncbi request reprint Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study
    Mohammed Sika
    Medicine, Vanderbilt, Nashville, TN, USA
    Am J Kidney Dis 50:78-89, 89.e1. 2007
    ....
  6. pmc Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis
    Tahira P Alves
    Department of Medicine, Division of Nephrology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Am Soc Nephrol 21:1361-9. 2010
    ..In conclusion, AASK participants were more likely to reach ESRD than to die...
  7. ncbi request reprint Microalbuminuria as a target to improve cardiovascular and renal outcomes
    Seema Basi
    Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 2372, USA
    Am J Kidney Dis 47:927-46. 2006
    ..These data suggest that urinary albumin should be measured routinely and treated to afford cardiovascular and renoprotection...
  8. pmc CRP polymorphisms and progression of chronic kidney disease in African Americans
    Adriana M Hung
    Vanderbilt University Medical Center, 1161 21st Avenue South and Garland, Division of Nephrology, S 3223 MCN, Nashville, TN 37232 2372, USA
    Clin J Am Soc Nephrol 5:24-33. 2010
    ..It is unknown if CRP polymorphisms are associated with CKD progression or modify the effectiveness of anti-hypertensive therapy in delaying CKD progression...
  9. pmc A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report
    Allison B McCoy
    Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA
    Am J Kidney Dis 56:832-41. 2010
    ..Frequently, prescribers fail to account for changing kidney function when prescribing medications. We evaluated the use of a computerized provider order entry intervention to improve medication management during acute kidney injury...
  10. doi request reprint Evaluation of renal artery stenosis in dialysis patients
    Jamie P Dwyer
    Division of Nephrology Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Semin Dial 22:519-23. 2009
    ..The risks of intervention must be weighed against the potential for renal recovery, even when predictors of success are not known with certainty...
  11. doi request reprint Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition
    Nicholas Stoycheff
    Division of Nephrology, Tufts Medical Center, Boston, MA 02111, USA
    Am J Kidney Dis 54:840-9. 2009
    ..These threshold levels have not been rigorously evaluated in patients with diabetic kidney disease or by using urine albumin excretion, the preferred measure of proteinuria in patients with diabetes...
  12. ncbi request reprint Use of calcium antagonists in renal patients: therapeutic benefit or medical malpractice?
    Douglas A Nigbor
    Division of Nephrology, Vanderbilt University Medical Center, S 3223 MCN, Nashville, TN 37232 2372, USA
    Curr Hypertens Rep 5:430-6. 2003
    ..However, there is no conclusive evidence that calcium channel blockers are injurious to the kidney, and they may be particularly beneficial in post-renal transplant patients...
  13. pmc Cardiovascular disease among hispanics and non-hispanics in the chronic renal insufficiency cohort (CRIC) study
    Ana C Ricardo
    Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
    Clin J Am Soc Nephrol 6:2121-31. 2011
    ..Hispanics are the largest minority group in the United States. The leading cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease (CVD), yet little is known about its prevalence among Hispanics with CKD...
  14. ncbi request reprint Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients
    Seema Basi
    Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Curr Diab Rep 7:439-42. 2007
    ..There is also evidence that reducing the level of albuminuria improves these outcomes. This review focuses on the most recent advances in this area and reviews literature over the past year on this topic...
  15. pmc Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations
    Lesley A Stevens
    Division of Nephrology, Tufts Medical Center, Boston, MA 02111, USA
    Am J Kidney Dis 54:33-42. 2009
    ....
  16. ncbi request reprint Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
    Tomas Berl
    University of Colorado Medical School, Denver, Colorado, USA
    Ann Intern Med 138:542-9. 2003
    ..The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause...
  17. ncbi request reprint Treatment of diabetic nephropathy with angiotensin II receptor antagonist
    Edmund J Lewis
    Rush Presbyterian St Luke s Medical Center, 1426 W Washington Blvd, Chicago, IL 60607, USA
    Clin Exp Nephrol 7:1-8. 2003
    ..Patients with type 2 diabetes and either early or late diabetic nephropathy should be treated with the angiotensin II receptor blocker irbesartan...
  18. ncbi request reprint Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?
    Seema Basi
    University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Diabetes Care 31:S194-201. 2008
  19. doi request reprint Aliskiren combined with losartan in type 2 diabetes and nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark
    N Engl J Med 358:2433-46. 2008
    ....
  20. doi request reprint Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans
    Lawrence J Appel
    Welch Center for Prevention, Epidemiology, and Clinical Research, The Johns Hopkins Institutions, Johns Hopkins University, Baltimore, MD 21205 2223, USA
    Arch Intern Med 168:832-9. 2008
    ..A low blood pressure (BP) goal (BP, <130/80 mm Hg) is also recommended. The objective of this study was to determine the long-term effects of currently recommended BP therapy in 1094 African Americans with hypertensive CKD...
  21. ncbi request reprint Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial
    Tomas Berl
    University of Colorado Health Sciences Center, 4200 East 9th Avenue, C 281, Denver, CO 80262, USA
    J Am Soc Nephrol 16:2170-9. 2005
    ..It is concluded that achieved SBP approaching 120 mmHg and diastolic BP of 85 mmHg are associated with the best protection against CV events in these patients. BP < or =120/85 may be associated with an increase in CV events...
  22. doi request reprint Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis
    Gautam Bhave
    Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    J Urol 180:830-5; discussion 835. 2008
    ..We investigated the recently discovered association between gadolinium based magnetic resonance imaging contrast agents and the development of nephrogenic systemic fibrosis in patients with chronic kidney disease or acute kidney injury...
  23. ncbi request reprint Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy
    David Aguilar
    Division of Cardiology, University of Texas Health Science Center, Houston, 77030, USA
    Am J Cardiol 94:337-9. 2004
    ..During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs...
  24. ncbi request reprint ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?
    Edmund J Lewis
    Rush University Medical Center, Chicago, Illinois, USA
    J Am Soc Nephrol 15:1358-60. 2004
  25. ncbi request reprint Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy
    Robert C Atkins
    Department of Nephrology, Monash Medical Centre, Victoria, Australia
    Am J Kidney Dis 45:281-7. 2005
    ....

Research Grants5

  1. Treatment of Diabetic Nephropathy
    Julia Lewis; Fiscal Year: 2003
    ..A decline in proteinuria in subjects randomized to COX2 inhibitors would support consideration of a larger, long-term trial to examine the efficacy of COX2 inhibitors in preserving renal function. ..
  2. Treatment of Diabetic Nephropathy
    Julia Lewis; Fiscal Year: 2004
    ..Also the pilot study allows us to establish procedures, better estimate recruitment goals and establish safety for a larger trial. ..
  3. AASK Cohort Study
    Julia Lewis; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..